Take-off phase 2 funding to accelerate development of our cervical (pre)cancer prediction test

🎉 Time to celebrate our new Take Off 2 funding from NWO! 🎉

We got the great news that Predica Diagnostics secured the Take Off 2 funding to accelerate development of our cervical (pre)cancer prediction test (Take-off projects). Our targeted RNA-sequencing based diagnostic test will reduce the number of unnecessary follow-up diagnostic testing and unnecessary referrals to gynecologists. By identifying only those women who truly need further evaluation or treatment, we can provide peace of mind and minimize stress for healthy women who test false-positive during screening. And at the same time save on healthcare costs!

Our work is only possible with a great team and through collaboration with our partners and stakeholders. We thank all the people that support us and make our work possible, with a special shout-out to: Rijksdienst voor Ondernemend Nederland (RVO), NWO (Nederlandse Organisatie voor Wetenschappelijk Onderzoek), Oost NL, Novel-T , Briskr, Radboudumc, Innovation Industries, Andreas Kaufmann, TenWise B.V., AID Autoimmun Diagnostika GmbH , Techleapnl, our Radboudumc colleagues from Centre for Molecular and Biomolecular Informatics (CMBI), Gynecology and Medical Microbiology and many others that we may have missed to mention!
 
Follow us for more updates on our progress as we continue to drive innovation, break barriers, and make an impact for patients by early cancer detection.